EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Early circulating tumor DNA changes predict outcomes in head and neck cancer patients under re‐radiotherapy

Florian Janke iD, Florian Stritzke, Katharina Dvornikovich, Henrik Franke, Arlou Kristina Angeles, Anja Lisa Riediger, Simon Ogrodnik, Sabrina Gerhardt, Sebastian Regnery, Philipp Schröter, Lukas Bauer, Katharina Weusthof und 11 weitere

International Journal of Cancer · 2025

DOI: 10.1002/ijc.35152 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Florian Janke und 22 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Genome Research, German Cancer Research Center (DKFZ), Heidelberg, Germany. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Head and Neck Neoplasms, DNA Copy Number Variations. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Krebshilfe.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Local recurrence after radiotherapy is common in locally advanced head and neck cancer (HNC) patients. Re‐irradiation can improve local disease control, but disease progression remains frequent. Hence, predictive biomarkers are needed to adapt treatment intensity to the patient's individual risk. We quantified circulating tumor DNA (ctDNA) in sequential plasma samples and correlated ctDNA levels with disease outcome. Ninety four longitudinal plasma samples from 16 locally advanced HNC patients and 57 healthy donors were collected at re‐radiotherapy baseline, after 5 and 10 radiation fractions, at irradiation end, and at routine follow‐up visits. Plasma DNA was subjected to low coverage whole genome sequencing for copy number variation (CNV) profiling to quantify ctDNA burden. CNV‐based ctDNA burden was detected in 8/16 patients and 25/94 plasma samples. Ten additional ctDNA‐positive samples were identified by tracking patient‐specific CNVs found in earlier sequential plasma samples. ctDNA‐positivity after 5 and 10 radiation fractions (both: log‐rank, p = .050) as well as at the end of irradiation correlated with short progression‐free survival (log‐rank, p = .006). Moreover, a pronounced decrease of ctDNA toward re‐radiotherapy termination was associated with worse treatment outcome (log‐rank, p = .005). Dynamic ctDNA tracking in serial plasma beyond re‐radiotherapy reflected treatment response and imminent disease progression. In five patients, molecular progression was detected prior to tumor progression based on clinical imaging. Our findings emphasize that quantifying ctDNA during re‐radiotherapy may contribute to disease monitoring and personalization of adjuvant treatment, follow‐up intervals, and dose prescription.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNAHead and Neck NeoplasmsDNA Copy Number VariationsHumansMaleFemaleMiddle AgedAgedBiomarkers, TumorRe-IrradiationNeoplasm Recurrence, LocalAdultDisease ProgressionPrognosis

Stichwörter der Autor:innen

circulating tumor DNAcopy number variationshead and neck cancerpredictive biomarkerre‐radiotherapy

Substanzen

Circulating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • Division of Cancer Genome Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • German Center for Lung Research (DZL), TLRC Heidelberg, Heidelberg, Germany.
  • National Center for Tumor Diseases (NCT), Heidelberg, Germany.
  • Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
  • Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.
  • Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

ORCID-Profile: Florian Janke

Förderung

  • Deutsche Krebshilfe

Zitieren

APA

Janke, F., Stritzke, F., Dvornikovich, K., Franke, H., Angeles, A. K., Riediger, A. L., Ogrodnik, S., Gerhardt, S., Regnery, S., Schröter, P., Bauer, L., Weusthof, K., Görtz, M., Harrabi, S., Herfarth, K., Neelsen, C., Paech, D., Schlemmer, H. P., Abdollahi, A., …, & Held, T. (2025). Early circulating tumor DNA changes predict outcomes in head and neck cancer patients under re‐radiotherapy. International Journal of Cancer. https://doi.org/10.1002/ijc.35152

Vancouver

Janke F, Stritzke F, Dvornikovich K, Franke H, Angeles AK, Riediger AL, et al. Early circulating tumor DNA changes predict outcomes in head and neck cancer patients under re‐radiotherapy. International Journal of Cancer. 2025. doi:10.1002/ijc.35152

BibTeX
@article{Janke2025,
  author = {Janke, Florian and Stritzke, Florian and Dvornikovich, Katharina and Franke, Henrik and Angeles, Arlou Kristina and Riediger, Anja Lisa and Ogrodnik, Simon and Gerhardt, Sabrina and Regnery, Sebastian and Schröter, Philipp and Bauer, Lukas and Weusthof, Katharina and Görtz, Magdalena and Harrabi, Semi and Herfarth, Klaus and Neelsen, Christian and Paech, Daniel and Schlemmer, Heinz-Peter and Abdollahi, Amir and Adeberg, Sebastian and Debus, Jürgen and Sültmann, Holger and Held, Thomas},
  title = {Early circulating tumor DNA changes predict outcomes in head and neck cancer patients under re‐radiotherapy},
  journal = {International Journal of Cancer},
  year = {2025},
  doi = {10.1002/ijc.35152}
}
Kostenlos starten →